Clinical trials: Stage III Anal Cancer AJCC v8
Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
This phase II trial studies the side effects of LET-IMPT and standard chemotherapy, and how well they work in treating patients with newly diagnosed stage I-III anal canal squamous cell cancer.
- Conditions
- Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage II Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
- Trial name
- NCT03690921
- Testing
- Cisplatin, Fluorouracil, Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
This phase II trial studies the side effects of chemotherapy and intensity modulated radiation therapy in treating patients with low-risk HIV-associated anal cancer, and nivolumab after standard of care chemotherapy and radiation…
- Conditions
- AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma
- Trial name
- NCT04929028
- Testing
- Anoscopy, Biospecimen Collection, Capecitabine
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
This phase III trial investigates how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer.
- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8
- Trial name
- NCT03233711
- Testing
- Biopsy Procedure, Biospecimen Collection, Colonoscopy
- Where
- 896 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- National Cancer Institute (NCI)
Anal Cancer
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00093379
- Testing
- Capecitabine, Oxaliplatin, Radiation Therapy (XRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer
This trial studies the prevalence of anal dysplasia and anal cancer in patients with cervical, vaginal, and vulvar dysplasia and cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ, Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Trial name
- NCT02140021
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 409 people
- Sponsor
- M.D. Anderson Cancer Center
Anal Squamous Cell Carcinoma, Stage 0 Anal Cancer AJCC v8
4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer
This study determines whether a positron emission tomography (PET)/computed tomography (CT) 4-point scoring system may predict overall survival for anal squamous cell cancer patients.
- Conditions
- Anal Squamous Cell Carcinoma, Stage 0 Anal Cancer AJCC v8, Stage I Anal Cancer AJCC v8, Stage II Anal Cancer AJCC v8
- Trial name
- NCT05130073
- Testing
- Computed Tomography, Electronic Health Record Review, Follow-Up
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Anal Cancer, Colorectal Cancer
Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer
RATIONALE: An anal sphincter prosthesis may replace the need for a permanent colostomy and may improve the quality of life of patients who are undergoing surgery for anal or rectal cancer.
- Conditions
- Anal Cancer, Colorectal Cancer, Perioperative/Postoperative Complications
- Trial name
- NCT00059891
- Testing
- conventional surgery, management of therapy complications
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Localized Anal Carcinoma, Localized Anal Margin Carcinoma
Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment
This clinical trial studies how well ganglion impar neurolysis works to improve radiation-induced pain during the treatment of anal or perianal skin cancer that has not spread to other parts of the body (localized).
- Conditions
- Localized Anal Carcinoma, Localized Anal Margin Carcinoma, Stage 0 Anal Cancer AJCC v8, Stage I Anal Cancer AJCC v8
- Trial name
- NCT07112690
- Testing
- Electronic Health Record Review, Fluoroscopy, Ganglion Impar Neurolysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Anal Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003652
- Testing
- cisplatin, fluorouracil, neoadjuvant therapy
- Where
- 48 sites in France
- Volunteers
- 350 people
- Sponsor
- UNICANCER
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
This phase 3 trial compares the addition of nivolumab to chemotherapy (carboplatin and paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that has spread to other places in the body…
- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Recurrent Anal Squamous Cell Carcinoma
- Trial name
- NCT04444921
- Testing
- Carboplatin, Nivolumab, Paclitaxel
- Where
- 579 sites in United States
- Volunteers
- 205 people
- Sponsor
- National Cancer Institute (NCI)
Anal Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining radiation therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00003596
- Testing
- cisplatin, fluorouracil, mitomycin C
- Where
- 485 sites in United States, South Africa
- Volunteers
- 682 people
- Sponsor
- Radiation Therapy Oncology Group
Anal Cancer
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00324415
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- AIDS Malignancy Consortium